Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15
Phase 2 vaccine candidate, VLA15, is being evaluated for adult and pediatric indications in North America and Europe. Saint Herblain... View Article
Rare Diseases Research Challenges Call for proposals
The French Foundation for Rare Diseases, partner of the European Joint Programme for Rare Diseases EJPRD, is pleased to announce... View Article
New member | Restaart
Restaart laboratories offer a unique and ingenious multisensory experience that refuels our energy levels through short, fully guided, recovery sessions.... View Article
#Coronavirus | Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19
Valneva is leveraging its technical and platform capabilities to develop an inactivated, whole virus vaccine candidate against the current coronavirus... View Article
#Coronavirus | Eurofins Medical Device Testing commitment to support the safety and efficacy of devices used in the COVID-19 Crisis Response
NEWS PROVIDED BY Eurofins Medical Device Testing COVID-19 pandemic emergency is putting health care systems under severe strain, reflecting an... View Article
New member | CENTICH – VyV Group
The CENTICH is a private, non-profit organization, member of the French mutuality and the VyV group. It was created on... View Article
New member | Croda – Smart Science to Improve Lives
Established in 1925, Croda is the name behind high performance ingredients and technologies in some of the world’s biggest and... View Article
New member | Biowest – The serum specialist
Based in Nuaillé (Cholet), Biowest was founded in 1987. The company launched its activity by processing and distributing animal sera... View Article
Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer
• Step-1 primary endpoint met: 12-month survival rate in Tedopi® treated patients; • Complete analysis of Step-1 results and further... View Article
OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases
Under this amendment, OSE Immunotherapeutics will receive a €5 million milestone payment at the start of the Sjögren’s Phase 2... View Article